投资两家企业同日上市，武创投、武汉基金迎双喜

Core Insights - Two companies, He Yuan Bio and Xi'an Yicai, successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant achievement for Wu Chuang Investment and Wuhan Fund [1] Company Summaries - He Yuan Bio is the world's first innovative biopharmaceutical company to achieve "rice-based blood production," utilizing plant bioreactor technology to extract recombinant human serum albumin from rice endosperm cells, aiming to revolutionize the global albumin drug industry [3] - Xi'an Yicai is a leading company in the domestic 12-inch semiconductor silicon wafer sector, recognized for its differentiated technology and intellectual property, achieving significant product quality recognition from major chip manufacturers [3] Investment Activities - Wu Chuang Investment and Wuhan Fund have actively explored primary and secondary market investments, successfully supporting He Yuan Bio through multiple rounds of investment and participating in Xi'an Yicai's funding alongside deep collaboration with Yiswei Group [4] - The listing of He Yuan Bio and Xi'an Yicai represents the 86th and 87th companies that Wu Chuang Investment and Wuhan Fund have supported to go public, reflecting their commitment to supporting technological innovation in Wuhan [4] Future Plans - Wu Chuang Investment and Wuhan Fund plan to continue increasing support for cutting-edge technology fields such as new-generation information technology, artificial intelligence, and biotechnology, aiming to accelerate the transformation of scientific achievements into new industries and economic growth [4]